Roche’s Alecensa trumps Pfizer’s Xalkori in frontline ALK+ lung cancer
A little more than a year after Roche won an accelerated approval for Alecensa as a new drug for treatment-resistant ALK-positive non-small cell lung cancer, the cancer drug powerhouse has trumped Pfizer’s Xalkori as a frontline therapy, beating out their rival on progression-free survival.
Roche won the first approval for Alecensa based on evidence of tumor shrinkage in Phase II. Researchers also highlighted a 61% response rate in patients with brain or CNS metastases to help distinguish the new arrival.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
